Genesis Therapeutics is committed to unifying artificial intelligence and biotechnology to discover innovative treatments for patients suffering from severe conditions. At the forefront of small molecule drug discovery, Genesis leverages its proprietary AI platform, GEMS, to optimize and accelerate the drug development process. Through deep learning and molecular simulations, the company aims to tackle both data-poor and undruggable targets, enhancing the pipeline for groundbreaking therapeutics.